William Blair analyst Andrew Brackmann has maintained their neutral stance on HOLX stock, giving a Hold rating on November 5.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Brackmann’s rating is based on a combination of factors, including Hologic’s recent fiscal fourth-quarter results and future growth projections. The company reported revenue that exceeded expectations, with a notable performance in the Breast Health segment, which returned to growth. However, despite these positive results, there are several risks that could impact future performance.
Key concerns include the potential delay or failure of the pending take-private transaction, as well as the possibility of slower-than-expected growth in the Breast Health segment. Additionally, challenges such as sustaining growth in molecular diagnostics, achieving earnings growth that outpaces revenue, successfully integrating new acquisitions, and potential reductions in hospital capital expenditures contribute to the Hold rating. These factors suggest a cautious approach, balancing the company’s current performance with uncertainties in its future outlook.
In another report released on November 5, UBS also maintained a Hold rating on the stock with a $76.00 price target.